DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the VIMTA LABS LIMITED (VIMTALABS) share price today?

VIMTA LABS LIMITED (VIMTALABS) is trading at ₹559.2 on the NSE, down 0.93% on the day. Source: DocStoX.

What is the PE ratio of VIMTA LABS LIMITED?

VIMTA LABS LIMITED has a price-to-earnings (PE) ratio of 37.0 in the Healthcare sector.

What is the market capitalisation of VIMTA LABS LIMITED?

VIMTA LABS LIMITED has a market capitalisation of approximately ₹2,514 crore.

VIMTA LABS LIMITED

VIMTALABS·NSE·Healthcare

₹559.20▼ -5.25 (-0.93%)

Healthcare · Healthcare Technology

Revenue under pressure recently

Day₹550.00

₹562.90

52W₹376

₹90335%

Open

₹562.90

High

₹562.90

Low

₹550.00

Prev Close

₹564.45

Volume

98.8K

VWAP

₹554.97

Snapshot

Key fundamentals

Market Cap

₹2,514 Cr

P/E Ratio

36.96Expensive

P/B Ratio

5.47

EPS

₹15.13

Book Value

₹102.24

ROE

12.83%Average

ROCE

25.00%Efficient

Dividend Yield

0.36%

Debt / Equity

0.01Low

Face Value

₹2.00

52W High

₹902.65

52W Low

₹376.05

Sector

Healthcare

Industry

Healthcare Technology

Avoid

None moatHigh uncertainty

Fair value estimate

₹122

▼ 78.2%downside

Trading at ₹559 — 78% above our estimate

BearFair valueBull

₹104₹122₹187

/100

Business quality — Watch the fundamentals

Growth 0Profitability 68Efficiency 51Valuation 66

Plain English

Our view

Revenue under pressure recently
Virtually debt-free balance sheet
Revenue has been shrinking

Strengths

Virtually debt-free balance sheet
Capital is working hard (ROCE 25%)

Risks

Revenue has been shrinking

How we got there

Fair value methods

Residual income

13% ROE fading to 12% over ~3 yrs, on ₹102 book

₹104

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹187

Analyst target

No analyst coverage

—

Blended fair value₹122

What the numbers say

Investment thesis

Bull case

Virtually debt-free balance sheet
Capital is working hard (ROCE 25%)

Bear case

Revenue has been shrinking

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

37.0Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

12.8%Average

Above 15% is considered healthy for Indian equities

ROCE

25.0%Efficient

Above 18% means capital is working hard

Debt/Eq

0.01Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹2,514 Cr

P/B

5.47

EPS

₹15.13

Div Yield

0.36%

What changed

Recent changes

Foreign investors+0.3% stake last quarter

What matters

News impact

Overview

Valuation

Expensive

P/E 37.0×

Growth

Steady

+9% rev CAGR

Profitability

Healthy

12.8% ROE

Financial health

Rock solid

D/E 0.01

Momentum

N/A

No technicals

Today

Trading activity

Delivery %47.7%

Turnover₹548.38L Cr

Trades3,848

VWAP₹554.97

Face value₹2.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+9.0%

+14.3%

10Y

+11.4%

Profit

+18.1%

+29.9%

10Y

+29.2%

EPS

—

10Y

—

Profile

Pros

Company has reduced debt.
Company is almost debt free.
Company has delivered good profit growth of 30.0% CAGR over last 5 years

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Foreign investors bought 0.30 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

36%

Promoter

Promoters

35.9%-0.05

Public

25.0%-0.11

FII / FPI

4.9%+0.30

DII

0.1%+0.03

Others

34.1%

Total shareholders

51,623-2,844 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter35.85%

FII4.89%

DII0.14%

Public25.01%

Others34.11%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 1990, Vimta Labs Ltd is a contract research and testing services provider[1]